MedTrace Logo

[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

NCT04528199 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-01-16

No results posted yet for this study

Summary

The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of \[18F\]FLOR (FC303) PET/CT imaging to determine the presence or absence of metastatic prostate cancer. .

Conditions

Interventions

DRUG

[18F]FLOR (FC303) Injection

Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.

Sponsors & Collaborators

  • FutureChem

    collaborator INDUSTRY

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Steven Rowe, M.D., Ph.D. · Johns Hopkins University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-04-21
Completion
2023-04-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04528199 on ClinicalTrials.gov